Navigation Links
Pharmaleads' Lead Candidate for Pain, PL37, Enters Phase I
Date:10/2/2008

PARIS, October 2 /PRNewswire/ -- Pharmaleads has obtained from the French Medicine Agency (AFSSAPS) the authorization to perform a single ascending dose Phase I study with PL37, its lead compound for oral treatment of neuropathic pain.

Neuropathic pain is a major chronic pain condition, with an estimated prevalence in the world's population of up to 6%, according to the most recent surveys, with many causes such as shingles, herpes, diabetes, antiviral or antitumor chemotherapy surgery, or low back disorders. Neuropathic pain does not respond well to usual painkillers. Worldwide market for neuropathic pain is estimated to reach 5 billion USD by 2010.

This compound originates from the work of Pharmaleads' chief scientists, Professors Bernard P. Roques and Marie-Claude Fournie-Zaluski, and is a dual inhibitor of both enzymes responsible for the rapid degradation of enkephalins, the endogenous opiates. It therefore elicits an analgesic effect wherever enkephalins are produced as a response to a painful stimulus, and maintains a high level of these natural analgesic substances by preventing their rapid degradation.

According to Thierry Bourbie, Chairman and CEO of Pharmaleads, "PL37 is Pharmaleads' first compound to enter clinical development and the first representative of a totally new class of painkillers, hence confirming the validity of our science and chemistry, as well as our capabilities as a drug development company. Neuropathic pain remains poorly treated and there is an urgent need to develop and bring to patients and doctors a specific oral treatment that would be really active and well tolerated. This looks very promising."

Bernard P. Roques, Vice-President and CSO of Pharmaleads explains: "The inhibition of both enzymes, responsible for the inactivation, in the body, of naturally present opiates, enhances their analgesic properties. PL37 physiological action in all areas where pain is present leads to very promising prope
'/>"/>

SOURCE Pharmaleads
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4
2. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
3. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
4. Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040
5. InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies
6. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
7. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
8. BioVex Announces Regulatory Clearance to Commence a Clinical Study With ImmunoVEX HSV2; A Vaccine Candidate for Genital Herpes
9. Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
10. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
11. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, ... the second Phase III clinical study for Ozenoxacin, ... impetigo.  Medimetriks owns the exclusive U.S. rights to ... trial, conducted at 44 centers with an emphasis ... patients aged 2 months and older with a ...
(Date:7/30/2015)... 30, 2015 Vermillion, Inc. (VRML), ... disease, announced today it will report its ... market close on Thursday, August 13, 2015, ... webcast at 4:30pm Eastern.Conference Call and Webcast:  ... Eastern/1:30pm Pacific  Domestic: , 888-430-8691International: ...
(Date:7/30/2015)... -- Big Cloud Analytics, Inc. (BCA), a leading provider ... working with Intel Corporation to showcase Internet of ... Healthcare Technology Alliance. The recently formed alliance is ... technology companies and academic institutions. Its purpose is ... in rapidly evolving and growing areas of health ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 2Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 3
... The oncology market continues to be a rapid growth ... of successfully launching a new oncology product is a ... Marketing function. The regulatory environment, regional ... present significant challenges for Global Strategic Marketing (GSM) organizations. ...
... investment funds advised by Apax Partners ("Apax"), together with ... and the Public Sector Pension Investment Board ("PSP Investments"), ... KCI ) have approved the consortium,s acquisition ... or a total value of approximately $6.3 billion, including ...
Cached Medicine Technology:Global Strategic Marketing Key to Success in Oncology Launches in the Pharmaceutical Sector 2Kinetic Concepts Shareholders Approve Acquisition by Apax Partners, CPPIB and PSP Investments 2Kinetic Concepts Shareholders Approve Acquisition by Apax Partners, CPPIB and PSP Investments 3Kinetic Concepts Shareholders Approve Acquisition by Apax Partners, CPPIB and PSP Investments 4
(Date:7/30/2015)... ... ... Using the latest online digital technologies, happiness expert Kay Walker is on ... manage major depression. , “Suicide is 100% preventable. The problem is the medical community ... die needlessly everyday,” says Walker. “I’m out to end suicide. Some may say that’s ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... On July ... $2 billion in taxpayer money to fund the state’s large prison system, which has ... with the highest rates of incarceration. In light of President Obama’s recent reduction of ...
(Date:7/30/2015)... ... 30, 2015 , ... Ocean Hills Recovery has officially been accredited by CARF ... No recommendations means CARF found no areas in the OHR program that needed improvement, ... of all facilities receive. In addition, Ocean Hills was granted the maximum certification period ...
(Date:7/30/2015)... ... July 30, 2015 , ... The ... of the New Jersey Department of Health, has received a $2.9 million grant ... of the U.S. Department of Health and Human Services (HHS). NJII will help ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... InventHelp, ... from Texas, has designed a personal-care device that makes it easy to apply lotion ... could eliminate the need for assistance when applying lotion or medication to the back, ...
Breaking Medicine News(10 mins):Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 2Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 3Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:Ocean Hills Recovery Receives Accreditation from CARF International 2Health News:New Jersey Innovation Institute Awarded $2.9 Million Federal Grant to Advance Health Information Technology Services to Support Health Information Exchange 2Health News:InventHelp® Client Patents “My Back Buddy” – Device Could Apply Lotion to Hard-to-Reach Areas Easily 2
... Even non-obese people are at risk, researchers find , WEDNESDAY, ... major risk factor for obstructive sleep apnea, many non-obese people ... new study. , Among 5,426 non-obese adults (with a body-mass ... present in 54 percent. About half of those with the ...
... key target of an evolutionarily conserved protein that regulates ... in Nature , provides fundamental knowledge about key ... strategies and cancer therapies. Scientists have long ... fitness and longevity in most organisms ranging from single-celled ...
... Four suspects often found at the scene of the crime in ... in mice that are resistant to the disease, a team led ... Center reports in the June edition of Cancer Cell . ... the three protein receptors and the enzyme that makes them are ...
... June 10 As more and more employees become eligible ... and smaller percentage of them are actually signing up for ... of the Spencer,s Benefits Reports 2009 COBRA Survey. ... the 2008 plan year at companies covered by the survey, ...
... Seroquel, Zyprexa have been linked to certain health ... News) -- A U.S. Food and Drug Administration ... whether several powerful but controversial antipsychotic drugs be ... in question include new-generation "atypical" antipsychotics such as ...
... Education Newsletter Series for Healthcare Professionals , , ... syndrome characterized by localized, subcutaneous and/or submucosal swelling. Diagnosing ... there are multiple etiologies of this condition, all of ... healthcare professionals to understand the various causes of angioedema, ...
Cached Medicine News:Health News:Wistar Institute team finds key target of aging regulator 2Health News:Researchers identify four new targets for breast cancer 2Health News:Spencer's Benefits Reports COBRA Survey Finds Recession Takes Hold: More Were Eligible, Fewer Signed Up, Costs Stay High 2Health News:Spencer's Benefits Reports COBRA Survey Finds Recession Takes Hold: More Were Eligible, Fewer Signed Up, Costs Stay High 3Health News:Spencer's Benefits Reports COBRA Survey Finds Recession Takes Hold: More Were Eligible, Fewer Signed Up, Costs Stay High 4Health News:FDA Panel Mulls Newer Antipsychotics for Kids 2Health News:FDA Panel Mulls Newer Antipsychotics for Kids 3Health News:FDA Panel Mulls Newer Antipsychotics for Kids 4Health News:New Directions in Angioedema: A Focus on Etiologies and Clinical Approach 2
... communications software, including Remote Link and Central ... you the tools and choices to effectively ... Send patient tests via email, LAN or ... Philips Zymed Holter analysis applications are used. ...
... 12 gives you the detailed information you ... for your patients with palpitations, syncope and ... EASI Lead System, this transtelephonic cardiac event ... a derived 12-lead ECG. Comfortable for your ...
... the Zargis Acoustic Cardioscan Viewer Phonocardiogram (PCG). ... system that allows you to record, condition, ... an electronic stethoscope. The product acquires ... of up to four sites, and allows ...
... with the challenge of,controlling costs while ... patient data,management is critical. INFINITY modular,patient ... important clinical information,wherever you are in ... concept,makes your job easier. You can ...
Medicine Products: